144 related articles for article (PubMed ID: 20427432)
1. Biomarkers predicting recurrence and progression of ductal carcinoma in situ treated by lumpectomy alone.
Allred DC
J Natl Cancer Inst; 2010 May; 102(9):585-7. PubMed ID: 20427432
[No Abstract] [Full Text] [Related]
2. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
3. DCIS prognostic markers: a few new candidates emerge.
Nelson NJ
J Natl Cancer Inst; 2010 May; 102(9):588-90. PubMed ID: 20427428
[No Abstract] [Full Text] [Related]
4. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
5. The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?
Tubbs RR; Stoler MH
Mod Pathol; 2000 Jan; 13(1):1-3. PubMed ID: 10658903
[No Abstract] [Full Text] [Related]
6. Preoperative ultrasound radiomics analysis for expression of multiple molecular biomarkers in mass type of breast ductal carcinoma in situ.
Wu L; Zhao Y; Lin P; Qin H; Liu Y; Wan D; Li X; He Y; Yang H
BMC Med Imaging; 2021 May; 21(1):84. PubMed ID: 34001017
[TBL] [Abstract][Full Text] [Related]
7. Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS.
Paszat L; Sutradhar R; Zhou L; Nofech-Mozes S; Rakovitch E
Clin Breast Cancer; 2019 Feb; 19(1):35-46. PubMed ID: 30190195
[TBL] [Abstract][Full Text] [Related]
8. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast.
Provenzano E; Hopper JL; Giles GG; Marr G; Venter DJ; Armes JE
Eur J Cancer; 2003 Mar; 39(5):622-30. PubMed ID: 12628841
[TBL] [Abstract][Full Text] [Related]
9. Can some DCIS patients avoid adjuvant therapy? Still unknown.
Schmidt C
J Natl Cancer Inst; 2011 Apr; 103(7):530-1. PubMed ID: 21436062
[No Abstract] [Full Text] [Related]
10. What Can Molecular Diagnostics Add to Locoregional Treatment Recommendations for DCIS?
Shelley Hwang E; Thompson A
J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376162
[No Abstract] [Full Text] [Related]
11. Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy.
Molinaro AM; Sison JD; Ljung BM; Tlsty TD; Kerlikowske K
Breast Cancer Res Treat; 2016 Jun; 157(2):351-361. PubMed ID: 27146587
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
13. [Intracystic papillary carcinoma of the breast: report of three cases].
El mazghi A; Bouhafa T; Loukili K; El kacemi H; Lalya I; Kebdani T; Hassouni K
Pan Afr Med J; 2014; 18():207. PubMed ID: 25419333
[TBL] [Abstract][Full Text] [Related]
14. Luminal B breast tumors are not HER2 positive.
Bhargava R; Dabbs DJ
Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
[No Abstract] [Full Text] [Related]
15. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
16. Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast.
Perez AA; Balabram D; Rocha RM; da Silva Souza Á; Gobbi H
J Histochem Cytochem; 2015 Jun; 63(6):408-16. PubMed ID: 25711229
[TBL] [Abstract][Full Text] [Related]
17. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
Yang M; Moriya T; Oguma M; De La Cruz C; Endoh M; Ishida T; Hirakawa H; Orita Y; Ohuchi N; Sasano H
Pathol Int; 2003 Jul; 53(7):422-8. PubMed ID: 12828606
[TBL] [Abstract][Full Text] [Related]
18. Ductal carcinoma in situ, complexities and challenges.
Leonard GD; Swain SM
J Natl Cancer Inst; 2004 Jun; 96(12):906-20. PubMed ID: 15199110
[TBL] [Abstract][Full Text] [Related]
19. Not all ductal carcinoma in situ is created equal: can we avoid surgery for low-risk ductal carcinoma in situ?
Lippey J; Spillane A; Saunders C
ANZ J Surg; 2016 Nov; 86(11):859-860. PubMed ID: 27784140
[No Abstract] [Full Text] [Related]
20. The certainties and the uncertainties of ductal carcinoma in situ.
Morrow M
J Natl Cancer Inst; 2004 Mar; 96(6):424-5. PubMed ID: 15026460
[No Abstract] [Full Text] [Related]
[Next] [New Search]
